- Home
- TMDX vs KYMR Comparison
TMDX vs KYMR Comparison
Compare TMDX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMDX
- KYMR
- Stock Information
- Founded
- TMDX 1998
- KYMR 2015
- Country
- TMDX United States
- KYMR United States
- Employees
- TMDX N/A
- KYMR N/A
- Industry
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- TMDX Health Care
- KYMR Health Care
- Exchange
- TMDX Nasdaq
- KYMR Nasdaq
- Market Cap
- TMDX 4.0B
- KYMR 4.3B
- IPO Year
- TMDX 2019
- KYMR 2020
- Fundamental
- Price
- TMDX $130.67
- KYMR $58.56
- Analyst Decision
- TMDX Buy
- KYMR Strong Buy
- Analyst Count
- TMDX 12
- KYMR 18
- Target Price
- TMDX $128.92
- KYMR $65.56
- AVG Volume (30 Days)
- TMDX 868.2K
- KYMR 710.7K
- Earning Date
- TMDX 10-29-2025
- KYMR 10-30-2025
- Dividend Yield
- TMDX N/A
- KYMR N/A
- EPS Growth
- TMDX 2163.11
- KYMR N/A
- EPS
- TMDX 2.02
- KYMR N/A
- Revenue
- TMDX $531,292,000.00
- KYMR $44,711,000.00
- Revenue This Year
- TMDX $38.78
- KYMR $60.88
- Revenue Next Year
- TMDX $20.76
- KYMR N/A
- P/E Ratio
- TMDX $64.68
- KYMR N/A
- Revenue Growth
- TMDX 48.09
- KYMR N/A
- 52 Week Low
- TMDX $55.00
- KYMR $19.45
- 52 Week High
- TMDX $145.50
- KYMR $63.96
- Technical
- Relative Strength Index (RSI)
- TMDX 69.28
- KYMR 57.01
- Support Level
- TMDX $108.34
- KYMR $55.26
- Resistance Level
- TMDX $118.51
- KYMR $61.83
- Average True Range (ATR)
- TMDX 6.15
- KYMR 2.75
- MACD
- TMDX 1.78
- KYMR -0.62
- Stochastic Oscillator
- TMDX 86.45
- KYMR 37.87
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.